|Mr. Kent J. Thiry||Chairman & CEO||3.62M||11.8M||1956|
|Mr. Joel Ackerman||Chief Financial Officer||1.62M||N/A||1965|
|Mr. James K. Hilger||Chief Accounting Officer||751.65k||388.08k||1962|
|Ms. Kathleen Alyce Waters||Chief Legal Officer||1.18M||N/A||1968|
|Mr. Javier J. Rodriguez||Chief Exec. Officer of DaVita Kidney Care||6.13M||1.56M||1971|
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
DaVita Inc.’s ISS Governance QualityScore as of January 1, 2019 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 2; Compensation: 7.